Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941085 | 0.98 | KMT2A (0.55) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL27943531 | 0.98 | KMT2A (0.55) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL3070503 | 0.81 | KDM4E (0.44) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL3070506 | 0.81 | KDM4E (0.44) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL3776494 | 0.80 | MEN1 (0.41) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL9356593 | 0.76 | KDM4E (0.48) | KMT2AMEN1ALDH1A1KDM4ERAB9A | |
| SCHEMBL9356896 | 0.74 | KDM4E (0.52) | KMT2AMEN1ALDH1A1GAAKDM4E | |
| SCHEMBL27480008 | 0.74 | KMT2A (0.46) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL9130522 | 0.74 | KDM4E (0.39) | KMT2ALMNAMEN1NPSR1ALDH1A1 | |
| SCHEMBL9130518 | 0.74 | KDM4E (0.39) | KMT2ALMNAMEN1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006496-B1 | TIRE RUBBER COMPOSITION AND MANUFACTURING METHOD THEREFOR | BRIDGESTONE CORP (JP) | 2017-07-19 | — | — | EP | claimed |
| CN-106794125-B | NAT10 modulators for the treatment or prevention of laminopathies, aging and cancer | 剑桥企业有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| EP-3137077-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | Cambridge Enterprise Limited (GB) | 2017-03-08 | — | — | EP | disclosed |
| CN-105246966-A | Rubber composition for tire and method for producing same | BRIDGESTONE CORP | 2016-01-13 | — | — | CN | disclosed |
| WO-2015150824-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-10-08 | — | — | WO | disclosed |
| EP-1789427-B1 | PREPARATION OF PLATINUM(II) COMPLEXES | PLATCO TECHNOLOGIES PROPRIETAR (ZA) | 2009-05-20 | — | — | EP | disclosed |
| US-20040186156-A1 | Substituted N-(1,4,5,6,-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| US-6747046-B2 | ANTITUMOR, ANTI CELL PROLIFERATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-08 | — | — | US | disclosed |
| US-20030212121-A1 | Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | US | disclosed |
| WO-2003029223-A1 | SUBSTITUTED N-(1,4,5,6-TETRAHYDROCYCLOPENTAPYRAZOL-3-YL) DERIVATIVES AND THE USE OF THE SAME FOR THE TREATMENT OF CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | WO | disclosed |
| US-4032659-A | ADMINISTERING THIOSEMICARBAZONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4027039-A | ADMINISTERING AMINOGUANIDINE, GUANIDINE, OR 1-(SEC-BUTYLIDENEAMINO)GUANIDINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
| US-3980774-A | HYDRAZINE AND HYDRAZINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | LMNB2, LMNB1, LMNA | KMT2A 2087/4885LMNA 3/4885MEN1 824/4885 |
| US-20030212121-A1 | Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents | PTGIS, NPC1, APC | KMT2A 4766/4885LMNA 2920/4885MEN1 1814/4885 |
| US-20040186156-A1 | Substituted N-(1,4,5,6,-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents | PTGIS, NPC1, APC | KMT2A 4743/4885LMNA 2711/4885MEN1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.